We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medical Mktg | LSE:MMG | London | Ordinary Share | GB0004150685 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.75 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
21/5/2009 21:19 | Jura1 - Do you mean like David and Margret Best who had to suffer for so long recieving £500K per year? | bioinvest | |
21/5/2009 18:59 | What sort of disadvantage to non-nstitutional investors do you have in mind? | bennytheball | |
21/5/2009 15:37 | Also a fingers crossed that funding issues are being resolved. It would be nice to know that no shareholders are not going to be disadvantaged by any corporate actions during the next few months as the current management have had a year to sort things out. I am also still hopeful that they will consider the interest of all shareholders, not just institutional. | jura1 | |
21/5/2009 13:53 | Sorry for the smart (not) reply Benny. It was the product of a long & boring night shift. Fingers crossed for a Positive RNS soon. | tenapen | |
21/5/2009 08:18 | No idea what they were Kenny - I was asking. Yes, I'm always hopeful though, even if it's a damn long wait. | bennytheball | |
21/5/2009 07:54 | I see them as sells ! but you see them as buys, Benny ! no change to the share price | tenapen | |
21/5/2009 07:46 | bit of volume yesterday - someone buying again? | bennytheball | |
14/5/2009 16:20 | Please do not mention Cellfactors .... it still hurts. I half remember MMG are out of money in June 09 ! we need news soon. | tenapen | |
12/5/2009 10:39 | Benny You are right when are we going to see tangible developments, the replacement management have been in place for over a year, similiar timeframe to Cellfactors replacement management and am currently decorating the lounge with the worthless certs. | topcall | |
02/5/2009 07:46 | I see Inovio are merging with a company developing vaccines, VGX Pharmaceuticals. I wonder if there are other potential opportunities for merger that might be of interest to MMG. If Ruthenium is still as far away from clinical trials as the latest announcements suggest (still trying to understand the mechanisms of action, as I read it), and they're offloading Viratis after having put its work on ice, that leaves only Genvax likely to come up with news worthy of a re-rating before the cash runs out. I know we're all pleased that the current management aren't talking up the share price with over-optimistic statements regarding progress and deals, but we need some tangible developments soon and I'm getting worried about the silence re Genvax. MMG could look like a nice shell for someone to move into at this price! Ben SAN DIEGO, May 1, 2009 -- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in enabling the development of DNA vaccines using electroporation-base | bennytheball | |
29/4/2009 08:04 | They were not sells....at worst a buyer and seller being matched up. | sleepinggiant | |
28/4/2009 21:22 | Benny, there was 2 x 100k sells at the closing bell so do not worry about there being no free float of shares. :-) | tenapen | |
28/4/2009 20:29 | It was 10 times as many as traded yesterday B that tell you something. | mitzis | |
28/4/2009 20:28 | Thanks Mitzis. ~£20k - not earth-shattering but interesting. I can't access the detail so can't tell if a large buy or lots of small ones. In any event, to have such an impact the MMs must have run their book down, I guess understandably given the low volume recently. Which means if there's further interest we might get over 7.25p, which looks like a resistance level? Where to next? | bennytheball | |
28/4/2009 20:13 | 400k I think B.. | mitzis | |
28/4/2009 19:43 | What was the volume today? B | bennytheball | |
28/4/2009 17:00 | Thanks for that sleeping giant . ps what has MW got to say on the latest update..? | mitzis | |
28/4/2009 16:29 | They havent given up the DNA flu vaccines just pushed on with more important areas of Genvax....like Prostrate cancer | sleepinggiant | |
28/4/2009 15:43 | I'm buying. | mitzis | |
28/4/2009 12:32 | I dont know why its moving up. | mitzis | |
28/4/2009 11:59 | I think they have which is a shame as they say 10 million people will be infected in the UK alone. | mitzis | |
28/4/2009 08:06 | Does anyone know if this company has given up on it's developement of flu virus treatments? | weyweyumfozo | |
28/4/2009 07:10 | I wonder when we're going to get more news on this, from six weeks back: MMI advances prostrate cancer clinical trials Business Weekly - UK Cancer drug developer, Medical Marketing International (MMI), is pushing forwards with plans to take its commercial prostate cancer vaccine (GVX 3322) into Phase II clinical trials following the successful completion of preclinical equivalence studies. The Cambridge company's share price rose 6.1 per cent to 6.5p a share following the announcement that it is now in discussions with leading clinical oncologists to define the key parameters for a prostate cancer trial. | bennytheball |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions